Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC).

In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases.

A hand holding cancer cells with a magnifying glass, highlighting the company’s target of curing diseases.

SIL204’s innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies.

The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)’s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors.

While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.